Comparison of 10-year Overall Survival Between Patients with G1 and G2 Grade Ta Bladder Tumors

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2018 Apr 19

PMID 29668641

Citations 6

Authors

Daniel Balan

Orsolya Martha

Calin Bogdan Chibelean

Sabin Tataru

Septimiu Voidezan

Anca Sin

Victor Deliu Matei

Mihai Dorin Vartolomei

Giuseppe Lucarelli

Antonio Cioffi

Francesco Del Giudice

Ettore De Berardinis

Angela Borda

Gian Maria Busetto

Matteo Ferro

Akos Pytel

Daniel Porav-Hodade

Affiliations

Soon will be listed here.

Abstract

To compare long-term overall survival (OS) in patients with G1 and G2 grade Ta bladder cancer after transurethral resection of bladder tumors (TURBTs). Secondary aim was to investigate clinical and pathologic prognostic factors for OS of Ta patients, except G3/high grade (HG).A total of 243 patients, retrospectively selected, with Ta nonmuscle invasive bladder cancer (NMIBC) underwent TURBT between January 2006 and December 2008 (median follow-up 109 months). Inclusion criteria were: Ta at first manifestation, G1 or G2 grade with no associated carcinoma in situ (CIS). Seventy-nine patients were excluded due to concomitant CIS (1), G3/HG tumors (47), and lost to follow-up (31). Ethical approval was obtained from the Ethical Committee of the Mures County Hospital. Statistical analysis was performed using STATA 11.0.Following inclusion criteria, 164 patients with primary G1 or G2 Ta tumors, were enrolled. Recurrence was observed in 26 (15.8%) and progression in 5 (3%) patients. Ten-year survival in G1 patients was 67.8% (CI 54.3-78.1) and in G2 patients 59% (CI 49-67.3) (P = .31). Univariable and multivariable logistic regression analysis underlined that advanced age at diagnosis (hazard ratio [HR] 1.10) and no Bacillus Calmette-Guerin (BCG) treatment (HR 0.24 and 0.29) were independent predictors for death at 10 years after diagnosis.Long-term analysis confirms that patients with well differentiated (G1) and moderately well differentiated (G2) Ta tumors have similar OS. A longer OS was even reported in those who underwent BCG adjuvant therapy.

Citing Articles

Metabolomic Approaches for Detection and Identification of Biomarkers and Altered Pathways in Bladder Cancer.

di Meo N, Loizzo D, Pandolfo S, Autorino R, Ferro M, Porta C Int J Mol Sci. 2022; 23(8).

PMID: 35456991 PMC: 9030452. DOI: 10.3390/ijms23084173.

Difficulties in Diagnosing and Treating Disseminated Bacillus Calmette-Guérin (BCG) Infection After Intravesical BCG Therapy in a Patient with Liver Cirrhosis: A Case Report.

Vallilas C, Zachou M, Dolkiras P, Sakellariou S, Constantinou C, Flevari P Am J Case Rep. 2021; 22:e933006.

PMID: 34654796 PMC: 8525903. DOI: 10.12659/AJCR.933006.

Stratifying risk for multiple, recurrent, and large (≥3 cm) Ta, G1/G2 tumors in non-muscle-invasive bladder cancer.

Suh J, Jung J, Kwak C, Kim H, Ku J Investig Clin Urol. 2021; 62(4):408-415.

PMID: 34190435 PMC: 8246012. DOI: 10.4111/icu.20210017.

Targeting of miR-96-5p by catalpol ameliorates oxidative stress and hepatic steatosis in LDLr-/- mice via p66shc/cytochrome C cascade.

Zhang Y, Wang C, Lu J, Jin Y, Xu C, Meng Q Aging (Albany NY). 2020; 12(3):2049-2069.

PMID: 32023549 PMC: 7041734. DOI: 10.18632/aging.102721.

Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) non-muscle-invasive bladder cancer and with low and intermediate EORTC-risk score.

Simon M, Bosset P, Rouanne M, Benhamou S, Radulescu C, Molinie V PLoS One. 2019; 14(2):e0211721.

PMID: 30811419 PMC: 6392242. DOI: 10.1371/journal.pone.0211721.

References

Kobayashi H, Kikuchi E, Mikami S, Maeda T, Tanaka N, Miyajima A . Long term follow-up in patients with initially diagnosed low grade Ta non-muscle invasive bladder tumors: tumor recurrence and worsening progression. BMC Urol. 2014; 14:5. PMC: 3913327. DOI: 10.1186/1471-2490-14-5. View

Crivelli J, Xylinas E, Kluth L, Rieken M, Rink M, Shariat S . Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. Eur Urol. 2013; 65(4):742-54. DOI: 10.1016/j.eururo.2013.06.010. View

Oosterlinck W, Lobel B, Jakse G, Malmstrom P, Stockle M, Sternberg C . Guidelines on bladder cancer. Eur Urol. 2002; 41(2):105-12. DOI: 10.1016/s0302-2838(01)00026-4. View

Soukup V, Capoun O, Cohen D, Hernandez V, Babjuk M, Burger M . Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines.... Eur Urol. 2017; 72(5):801-813. DOI: 10.1016/j.eururo.2017.04.015. View

Alvarez A, Lokeshwar V . Bladder cancer biomarkers: current developments and future implementation. Curr Opin Urol. 2007; 17(5):341-6. DOI: 10.1097/MOU.0b013e3282c8c72b. View

Herr H . Age and outcome of superficial bladder cancer treated with bacille Calmette-Guérin therapy. Urology. 2007; 70(1):65-8. DOI: 10.1016/j.urology.2007.03.024. View

Gardmark T, Jahnson S, Wahlquist R, Wijkstrom H, Malmstrom P . Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer. BJU Int. 2007; 99(4):817-20. DOI: 10.1111/j.1464-410X.2006.06706.x. View

Sylvester R, van der Meijden A, Oosterlinck W, Witjes J, Bouffioux C, Denis L . Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006; 49(3):466-5. DOI: 10.1016/j.eururo.2005.12.031. View

Vartolomei M, Kiss B, Vidal A, Burkhard F, Thalmann G, Roth B . Long-term results of a prospective randomized trial assessing the impact of re-adaptation of the dorsolateral peritoneal layer after extended pelvic lymph node dissection and cystectomy. BJU Int. 2015; 117(4):618-28. DOI: 10.1111/bju.13178. View

10.

Koie T, Ohyama C, Hosogoe S, Yamamoto H, Imai A, Hatakeyama S . Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer. Int Urol Nephrol. 2015; 47(9):1509-14. DOI: 10.1007/s11255-015-1048-3. View

11.

Gupta S, Parr N . Outcome of very large superficial bladder tumours: a 10-year experience. Scand J Urol Nephrol. 2008; 42(3):243-8. DOI: 10.1080/00365590701832759. View

12.

Yoo K, Lim T, Chang S . Monthly intravesical bacillus Calmette-Guérin maintenance therapy for non-muscle-invasive bladder cancer: 10-year experience in a single institute. Exp Ther Med. 2012; 3(2):221-225. PMC: 3438621. DOI: 10.3892/etm.2011.400. View

13.

Cotte J, Roupret M . Re: Long-term Oncological Outcomes of an Active Surveillance Program in Recurrent Low Grade Ta Bladder Cancer. Eur Urol. 2017; 72(1):152. DOI: 10.1016/j.eururo.2017.02.017. View

14.

Rieken M, Xylinas E, Kluth L, Crivelli J, Chrystal J, Faison T . Long-term cancer-specific outcomes of TaG1 urothelial carcinoma of the bladder. Eur Urol. 2013; 65(1):201-9. DOI: 10.1016/j.eururo.2013.08.034. View

15.

Tang X, Du P, Yang Y . The clinical use of neutrophil-to-lymphocyte ratio in bladder cancer patients: a systematic review and meta-analysis. Int J Clin Oncol. 2017; 22(5):817-825. DOI: 10.1007/s10147-017-1171-5. View

16.

Davis J, Sheth S, Doviak M, Schellhammer P . Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10-year followup. J Urol. 2002; 167(2 Pt 1):494-500; discussion 501. DOI: 10.1016/S0022-5347(01)69072-4. View

17.

Cheng C, Chan S, Chan L, Chan C, Ng C, Cheung H . Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer. Int J Urol. 2005; 12(5):449-55. DOI: 10.1111/j.1442-2042.2005.01064.x. View

18.

Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat E . EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2016; 71(3):447-461. DOI: 10.1016/j.eururo.2016.05.041. View

19.

Gardmark T, Bladstrom A, Hellsten S, Malmstrom P . Analysis of clinical characteristics, management and survival of patients with Ta T1 bladder tumours in Sweden between 1997 and 2001. Scand J Urol Nephrol. 2006; 40(4):276-82. DOI: 10.1080/00365590600744238. View

20.

Low V, Wang D, Abel P . Survival of patients with bladder cancer from a UK hospital: a 10-year follow-up study. BJU Int. 2010; 105(12):1667-71. DOI: 10.1111/j.1464-410X.2009.09071.x. View